Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use

Overview of attention for article published in Pediatric Nephrology, November 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#46 of 4,023)
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

policy: 1 policy source
twitter: 37 X users

patent: 1 patent
facebook: 4 Facebook pages

Citations

dimensions_citation: 72 Dimensions

Readers on

mendeley: 115 Mendeley

Summary Policy documents X Patents Facebook Dimensions citations

So far, Altmetric has seen 1 patent that references this research output.

IPTACOPAN FOR THE TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME

Application WO-2022234541-A1

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.